John Xu, MD, MBA, MS

John Xu, MD, MBA, MS has worked for several companies in the biotechnology and pharmaceutical industry. In 1996, they began their career as an Associate Scientist II at Bristol-Myers Squibb. In 2000, they moved to Wyeth as a Senior Research Scientist. In 2010, they joined ShanghaiBio as Director of Project Management. In 2013, they became Senior Director of Business Development at WuXi AppTec. In 2015, they were appointed Executive Director of Business Development at Crown Bioscience, Inc. In 2016, they were promoted to Vice President, Global Business Development at HD Biosciences Co., Ltd. In 2017, they rejoined Abpro as Senior Vice President of Strategic Alliances. In 2018, they became the CEO and Co-founder at Jemincare Therapeutics Corp. In 2019, they were promoted to SVP, Head of China Business Development at Abpro. Most recently, in 2022, they were appointed Chief Business Officer at Hopstem Biotechnology Co., Ltd.

John Xu, MD, MBA, MS holds a Doctor of Medicine (MD) from Shanghai Medical College of Fudan University, a Master of Science (M.S.) in Biological Chemistry from Chicago Medical School at Rosalind Franklin U-Med & Science, and a Master of Business Administration (MBA) in Health Care Administration from the University of Colorado Colorado Springs.